Literature DB >> 8249054

A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma.

A Andersen1, D J Warren, L Slørdal.   

Abstract

A sensitive high-performance liquid chromatographic (HPLC) method for the measurement of doxorubicin and its metabolites in plasma is described. After precipitation with zinc sulphate and methanol, samples are resolved by isocratic elution from a C18 reverse phase support within 20 min and quantified by endogenous fluorescence. Recoveries over a concentration range from 5 to 1,000 nM of doxorubicin, doxorubicinol, doxorubicinone, doxorubicinolone, and 7-deoxydoxorubicinolone were 80-110%, while recovery for 7-deoxydoxorubicinone was approximately 60%. At concentrations of 5 nM, within-run and between-day coefficients of variation for each compound were < 8 and < 16%, respectively. Limits of detection for the compounds were 1-2 nM and standard curves were linear up to at least 1,000 nM. The drug and its metabolites are stable in deproteinized plasma samples at room temperature and in the dark for at least 24 h. The method requires few manipulations and is readily adaptable to automated analysis of large series of samples.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249054     DOI: 10.1097/00007691-199310000-00016

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography.

Authors:  David L Chin; Bert L Lum; Branimir I Sikic
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-05       Impact factor: 3.205

2.  Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.

Authors:  Robert D Arnold; Jeanine E Slack; Robert M Straubinger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-05       Impact factor: 3.205

3.  An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

Authors:  H Hirte; D Stewart; R Goel; E Chouinard; S Huan; S Stafford; B Waterfield; S Matthews; C Lathia; B Schwartz; V Agarwal; R Humphrey; And L Seymour
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

4.  Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

Authors:  A Andersen; D J Warren; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia.

Authors:  Gerald J Fetterly; Urvi Aras; Deepika Lal; Michael Murphy; Patricia D Meholick; Eunice S Wang
Journal:  AAPS J       Date:  2013-04-03       Impact factor: 4.009

6.  Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.

Authors:  Pei Jye Voon; Hui Ling Yap; Cho-Yee-Thu Ma; Fan Lu; Andrea L A Wong; Nur Sabrina Sapari; Richie Soong; Thomas I P Soh; Boon-Cher Goh; How-Sung Lee; Soo-Chin Lee
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

7.  Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

Authors:  Peter L Greenberg; Sandra J Lee; Ranjana Advani; Martin S Tallman; Branimir I Sikic; Louis Letendre; Kathleen Dugan; Bert Lum; David L Chin; Gordon Dewald; Elisabeth Paietta; John M Bennett; Jacob M Rowe
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

8.  Effect of coenzyme Q10 on the disposition of doxorubicin in rats.

Authors:  Qingyu Zhou; Balram Chowbay
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jul-Sep       Impact factor: 2.569

9.  Bioanalysis of doxorubicin aglycone metabolites in human plasma samples-implications for doxorubicin drug monitoring.

Authors:  Christian Siebel; Claudia Lanvers-Kaminsky; Gudrun Würthwein; Georg Hempel; Joachim Boos
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.